Summary: Age-related macular degeneration (AMD) remains a leading cause of vision loss worldwide, but recent therapeutic advances are changing the outlook. Newly approved complement inhibitors—pegcetacoplan and avacincaptad pegol—slow the progression of geographic atrophy in dry AMD, while innovations in wet AMD therapies, gene-based treatments, cell therapy, and non-invasive approaches are expanding options and lowering treatment burden for patients.
Anti-VEGF agents still form the backbone of wet AMD care, but next-generation drugs and combination strategies promise longer dosing intervals and improved durability. At the same time, research into gene therapies, stem cell approaches, and photobiomodulation is progressing, offering potential future alternatives that may complement or transform current standards.
Key Facts:
- Complement inhibitors approved: Pegcetacoplan (C3 inhibitor) and avacincaptad pegol (C5 inhibitor) slow geographic atrophy growth, with reported reductions in lesion progression in clinical trials.
- Wet AMD innovation: Faricimab, a bispecific antibody targeting VEGF and angiopoietin-2, enables extended dosing intervals for many patients, reducing injection frequency.
- Emerging options: Gene therapy, stem cell-based treatments, and photobiomodulation show promise but remain under investigation and require further validation.
Source: FAR Publishing Ltd
Overview
Age-related macular degeneration (AMD) is a major cause of vision loss in older adults and presents in two main forms: dry AMD, which can progress to geographic atrophy (GA), and wet AMD, driven by abnormal blood vessel growth. Treatment progress over recent years has focused on addressing underlying inflammation, complement activation, and vascular proliferation that contribute to retinal damage.
Clinical research and regulatory approvals have introduced new approaches for dry AMD that were previously lacking. Pegcetacoplan and avacincaptad pegol target components of the complement cascade, interrupting pathways that drive chronic inflammation and tissue loss in GA. In trials, pegcetacoplan reduced GA lesion growth modestly, while avacincaptad pegol demonstrated larger percentage reductions, offering the first pharmacologic options that can slow structural progression in some patients.
For neovascular (wet) AMD, anti-VEGF therapies continue to be highly effective at controlling vision loss. New agents aim to extend the interval between injections and to improve response durability. Faricimab, a bispecific antibody that blocks both VEGF and angiopoietin-2, has enabled treatment intervals up to 16 weeks for many patients in clinical practice and trials, reducing the frequency and burden of intravitreal injections.
Combination strategies are an active area of development. Combining complement inhibition with anti-VEGF therapy or using dual-targeting molecules may tackle multiple disease pathways at once, potentially improving outcomes for patients with mixed or refractory disease. One example in clinical development is a dual-targeting compound that simultaneously addresses complement-mediated inflammation and angiogenic signaling.
Photobiomodulation (low-level light therapy) has emerged as a non-invasive approach under study for dry AMD. Some trials have reported improvements in visual function measures, although evidence is still limited and further controlled studies are needed to define optimal protocols and long-term benefits. Meanwhile, gene therapies such as RGX-314 and stem cell-based retinal repairs aim to provide sustained therapeutic effects but are currently experimental and subject to ongoing clinical evaluation.
While these advances are encouraging, they are accompanied by new safety considerations and practical challenges. For example, inflammatory events, including retinal vasculitis, have been reported with certain complement-targeting agents, highlighting the need for careful patient selection, monitoring, and risk mitigation. Additionally, access, cost, and long-term effectiveness remain important questions as therapies move from trials into routine care.
In sum, the AMD treatment landscape is evolving rapidly. Approved complement inhibitors and longer-acting anti-VEGF options are changing how clinicians manage dry and wet AMD, and a pipeline of gene, cell, and device-based therapies may further expand choices. Ongoing research into combination regimens and personalized treatment approaches seeks to optimize outcomes while minimizing risks and treatment burden for patients living with AMD.
About this AMD and vision loss research news
Author: Chris Zhou
Source: FAR Publishing Ltd
Contact: Chris Zhou – FAR Publishing Ltd
Image: The image is credited to Neuroscience News
Original Research: Open access. “Recent Advancements in the Treatment of Age-Related Macular Degeneration” by Shan Liu et al., published in Med Research. DOI: 10.1002/mdr2.70009
Abstract
Recent Advancements in the Treatment of Age-Related Macular Degeneration
AMD is a leading cause of visual impairment in older adults. The two main subtypes—dry and wet AMD—have distinct pathologies and treatment needs. Wet AMD is primarily treated with anti-VEGF agents, which are effective but often require frequent intravitreal injections and may not fully prevent long-term complications such as fibrosis. Dry AMD, particularly geographic atrophy, has historically lacked effective medical therapies until recent approvals targeting the complement pathway.
Current and emerging therapies address different disease mechanisms, including angiogenesis, complement-mediated inflammation, and cellular degeneration. Clinical trials and real-world experience continue to refine indications, dosing strategies, and safety profiles, while research into combination therapies and precision medicine aims to improve individualized care for patients living with AMD.